6/11/2013

The FDA turned down Aveo Oncology's application for tivozanib as a treatment for advanced renal cell carcinoma, citing inconsistent trial data that made the results "uninterpretable and inconclusive." The agency asked Aveo to conduct another clinical trial to win approval.

Full Story:
USA Today, Xconomy

Related Summaries